Pfizer Receives FDA Approval for EUCRISA™ (crisaborole), a Novel Non-Steroidal Topical Ointment for Mild to Moderate Atopic Dermatitis (Eczema)

December 15, 2016 Scipreneur Private Limited 0

Pfizer Receives FDA Approval for EUCRISA™ (crisaborole), a Novel Non-Steroidal Topical Ointment for Mild to Moderate Atopic Dermatitis (Eczema) Pfizer News December 15, 2016  Pfizer Inc. (NYSE:PFE) announced that the U.S. Food and Drug Administration (FDA) approved EUCRISATM (crisaborole) ointment 2%, a novel non-steroidal topical phosphodieterase-4 (PDE-4) inhibitor for the treatment [..]

Big Data is Manageable: MIT Research

December 15, 2016 Scipreneur Private Limited 0

Big Data is Manageable: MIT Research By: Larry Hardesty | MIT News Office December 15, 2016 One way to handle big data is to shrink it. If you can identify a small subset of your data set that preserves its salient mathematical relationships, you may be able to perform useful [..]

Possible Drug Treatment For Incurable Brain Cancer

December 15, 2016 Scipreneur Private Limited 0

Possible Drug Treatment For Incurable Brain Cancer University of Toronto News December 15, 2016 A  team of University of Toronto researchers has identified promising drugs that could target a type of incurable brain cancer in children. That discovery is one of the potential outcomes of research described in the December 12 [..]

Three Diseases and One Stone

December 14, 2016 Scipreneur Private Limited 0

Three Diseases and One Stone By: Elizabeth Dougherty December 14, 2016 In large swaths of rural Latin America, an insect called the kissing bug spreads a silent killer: Chagas disease. A bug bite can transfer a single-celled organism that takes up residence in several different tissues. People can live with these [..]

Novartis provides update on pegpleranib Phase III clinical trial program in patients with neovascular age-related macular degeneration (nAMD or wet AMD)

December 13, 2016 Scipreneur Private Limited 0

Novartis provides update on pegpleranib Phase III clinical trial program in patients with neovascular age-related macular degeneration (nAMD or wet AMD) Recent Lucentis EU approval in new choroidal neovascularization (CNV)  indication demonstrates Novartis’ strong commitment to innovate and grow Lucentis (ranibizumab) as standard of care in diseases of the retina [..]

IISR 2017 — Investigator Initiated and Sponsored Research

December 12, 2016 Scipreneur Private Limited 0

IISR 2017 — Investigator Initiated and Sponsored Research PROGRESSIVE SOLUTIONS FOR IISR PROGRAM DEVELOPMENT, NEGOTIATIONS AND RESULTS REPORTING FEBRUARY 13-14, 2017 | DOUBLETREE CENTER CITY | PHILADELPHIA, PA With the continued evolution of transparency and reporting regulations, CBI’s 5th annual Investigator Initiated and Sponsored Research conference creates a platform to [..]

Eli Lilly and AstraZeneca Going to Co-develop Modifying Treatment for Alzheimer’s Disease

December 11, 2016 Scipreneur Private Limited 0

Eli Lilly and AstraZeneca Going to Co-develop Modifying Treatment for Alzheimer’s Disease  December. 12, 2016 (PRNewswire) Eli Lilly and Company (NYSE: LLY) and AstraZeneca announced a worldwide agreement to co-develop MEDI1814, an antibody selective for amyloid-beta 42 (Aβ42), which is currently in Phase 1 trials as a potential disease-modifying treatment [..]

New And Emerging Technologies Conference

December 11, 2016 Scipreneur Private Limited 0

New And Emerging Technologies Conference January 30-February 1, 2017 at San Diego, CA  The Annual New and Emerging Technologies Conference, organized by the Touchstone Energy Cooperatives will take place from 30th January to the 1st February 2017 at the Loews Coronado Bay Resort in San Diego, United States Of America. [..]

Now Unwanted CRISPR-Cas9 Gene Edits Can be Controlled

December 11, 2016 Scipreneur Private Limited 0

Now Unwanted CRISPR-Cas9 Gene Edits Can be Controlled By: University Of Toronto News December 11, 2016 CRISPR genome editing is quickly revolutionizing biomedical research, but the new technology is not yet exact. The technique can inadvertently make excessive or unwanted changes in the genome and create off-target mutations, limiting safety and [..]

Novartis LEE011 (ribociclib) plus letrozole analyses show superior PFS across broad spectrum of patients in first-line HR+/HER2- advanced breast cancer versus letrozole

December 10, 2016 Scipreneur Private Limited 0

Novartis LEE011 (ribociclib) plus letrozole analyses show superior PFS across broad spectrum of patients in first-line HR+/HER2- advanced breast cancer versus letrozolev LEE011 plus letrozole reduced risk of progression or death by 55% over letrozole alone in de novopatients, and by 54% in patients with three or more metastases – [..]

Creating Clinical Bioengineers

December 10, 2016 Scipreneur Private Limited 0

Creating Clinical Bioengineers By: UCSD News December 10, 2016 A group of UC San Diego bioengineering students huddle around a computer screen as colored images of blood being pumped through a heart flash across the screen. The students are observing as a physician annotates an MRI of a patient’s heart and [..]

New Evidence Shows how Bacterium In Undercooked Chicken Causes Guillain-Barre Syndrome

December 10, 2016 Scipreneur Private Limited 0

New Evidence Shows how Bacterium In Undercooked Chicken Causes Guillain-Barre Syndrome By: Linda Mansfield, Sarina Gleason (Michigan State University) A  Michigan State University research team is the first to show how a common bacterium found in improperly cooked chicken causes Guillain-Barre Syndrome, or GBS. The federally funded research, now published in the [..]

Flexible Device Captures Energy From Human Motion

December 10, 2016 Scipreneur Private Limited 0

Flexible Device Captures Energy From Human Motion By: Nelson Sepulveda, Andy Henion (Michigan State University) December 10, 2016 The day of charging cellphones with finger swipes and powering Bluetooth headsets simply by walking is now much closer. Michigan State University engineering researchers have created a new way to harvest energy from [..]

Novartis’ Ultibro® Breezhaler® improved lung function and COPD symptoms after direct switch from previous treatment

December 9, 2016 Scipreneur Private Limited 0

Novartis’ Ultibro® Breezhaler® improved lung function and COPD symptoms after direct switch from previous treatment   Results further support the 2017 GOLD recommendations that dual bronchodilation should be the foundation treatment for the majority of symptomatic COPD patients   Data from the pragmatic CRYSTAL study showcased for the first time [..]

Protein Disrupts Infectious Biofilms

December 9, 2016 Scipreneur Private Limited 0

Protein Disrupts Infectious Biofilms  Many infectious pathogens are difficult to treat because they develop into biofilms, layers of metabolically active but slowly growing bacteria embedded in a protective layer of slime, which are inherently more resistant to antibiotics. Now, a group of researchers at Caltech and the University of Oxford [..]